Lexaria Bioscience Förvaltning

Förvaltning kriterier kontrolleras 1/4

Lexaria Bioscience VD är Rich Christopher, utsedd i Aug 2024, har en anställningstid på mindre än ett år. äger direkt 0.28% av företagets aktier, värda $ 64.00K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 0.5 år respektive 2.2 år.

Viktig information

Rich Christopher

Verkställande direktör

US$519.3k

Total ersättning

VD-lön i procent	n/a
Anställning som VD	less than a year
Ägande av VD	0.3%
Ledningens genomsnittliga anställningstid	less than a year
Styrelsens genomsnittliga mandatperiod	2.2yrs

Senaste uppdateringar av ledningen

Recent updates

VD OCH KONCERNCHEF

Rich Christopher (54 yo)

less than a year

Anställning

US$519,317

Kompensation

Mr. Richard C. Christopher, also known as Rich, is Chief Executive Officer of Lexaria Bioscience Corp. from August 31, 2024 and served as its Director since 2025. He served as Chief Financial Officer and T...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Richard Christopher	CEO & Director	less than a year	US$519.32k	0.28% $ 64.0k
John Docherty	Chairman of the Scientific Advisory Board	9.9yrs	US$414.42k	0% $ 0
Michael Shankman	Chief Financial Officer	less than a year	inga uppgifter	inga uppgifter
Kristin Hamilton	Director of Operations	no data	inga uppgifter	inga uppgifter
Vanessa Carle	Head of Legal	no data	inga uppgifter	inga uppgifter
C. Gibson	Chief Medical Advisor & Member of Scientific Advisory Board	less than a year	inga uppgifter	inga uppgifter

0.5yrs

Genomsnittlig anställningstid

55yo

Genomsnittlig ålder

Erfaren ledning: LEXX s ledningsgrupp anses inte vara erfaren ( 0.5 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Richard Christopher	CEO & Director	less than a year	US$519.32k	0.28% $ 64.0k
John Docherty	Chairman of the Scientific Advisory Board	8.9yrs	US$414.42k	0% $ 0
C. Gibson	Chief Medical Advisor & Member of Scientific Advisory Board	less than a year	inga uppgifter	inga uppgifter
Albert Reese	Independent Director	4.2yrs	US$74.83k	0.062% $ 14.0k
Christopher Bunka	Chairman of the Board	18.4yrs	US$884.84k	2.13% $ 478.1k
Nicholas Baxter	Independent Director	13.7yrs	US$74.83k	0.063% $ 14.1k
William McKechnie	Independent Director	9.5yrs	US$69.83k	0.075% $ 16.9k
Baljinder Bhullar	Director	less than a year	inga uppgifter	0.074% $ 16.6k
Philip Ainslie	Member of Scientific Advisory Board	less than a year	inga uppgifter	inga uppgifter
Karen Aust	Member of Scientific Advisory Board	less than a year	inga uppgifter	inga uppgifter

2.2yrs

Genomsnittlig anställningstid

62yo

Genomsnittlig ålder

Erfaren styrelse: LEXX s styrelse anses inte vara erfaren ( 2.2 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/04 23:07
Aktiekurs vid dagens slut	2025/03/04 00:00
Intäkter	2024/11/30
Årlig intjäning	2024/08/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Lexaria Bioscience Corp. bevakas av 4 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Ammar Shah	Eight Capital
Yi Chen	H.C. Wainwright & Co.
Michael Okunewitch	Maxim Group

Lexaria Bioscience Förvaltning

Förvaltning kriterier kontrolleras 1/4

Viktig information

Senaste uppdateringar av ledningen

Less than half of directors are independent

Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board

Chief Executive Officer recently bought US$51k worth of stock

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Recent updates

New minor risk - Share price stability

Lexaria Bioscience Corp. Announces Dosing Has Begun in Its Fluorescently Tagged Dehydratech-Semaglutide Rodent Biodistribution Study

New major risk - Revenue and earnings growth

Less than half of directors are independent

Consensus revenue estimates fall by 12%

Lexaria Bioscience Corp. Announces Partial Final Results Showcasing the Tolerability and Glycemic Control Efficacy Findings from Human Study GLP-1- H2 4-3

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Begins Dosing in its Phase 1B, 12-Week Chronic Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board

Lexaria Bioscience Corp. Announces Engagement of Contract Research Organization to Design and Execute Human Pilot Study Evaluating Dehydratech-Liraglutide Against Saxenda Injectable Liraglutide

Chief Executive Officer recently bought US$51k worth of stock

Consensus revenue estimates fall by 13%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria Bioscience Corp.'s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Lexaria Bioscience Corp. Receives Final 12-Week Body Weight and Blood Sugar Results from All 12 Study Groups of the Recently Completed Diabetes Animal Study

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Announces Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives Partial 12-Week Body Weight Results from the Recently Completed Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Begins Dosing in Human Pilot Study for Oral Tirzepatide Using Dehydratech Technology

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Lexaria Bioscience Corp. Announces Second GLP-1 Human Pilot Study Shows Zero Adverse Events in Dehydratech-Processed Rybelsus Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives 4-Week and 8-Week Blood Sugar Results from Ongoing Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. Announces Positive Results from Lexaria's Molecular Characterization Study

Consensus revenue estimates fall by 24%

Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2

Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study

Consensus revenue estimates increase by 24%

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study

Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023)

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1

Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. Submits Investigational New Drug Application

Consensus revenue estimates increase by 100%

Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023)

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update

Consensus revenue estimates decrease by 20%, EPS upgraded

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million.

Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1

Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress

Consensus revenue estimates increase by 38%, EPS downgraded

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD